Page last updated: 2024-12-09
cefsulodin sodium
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 656644 |
| CHEMBL ID | 1590946 |
| CHEBI ID | 31380 |
| SCHEMBL ID | 1648651 |
| MeSH ID | M0330934 |
Synonyms (71)
| Synonym |
|---|
| cefsulodin sodium salt |
| takesulin |
| pseudocef |
| pseudomonil |
| abbott-46811 |
| cgp-7174/e |
| tilmapor |
| sulcephalosporin |
| EU-0100259 |
| pyridinium, 4-(aminocarbonyl)-1-((2-carboxy-8-oxo-7-((phenylsulfoacetyl)amino)-5-thio-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, hydroxide, inner salt, monosodium salt, (6r-(6-alpha,7-beta(r*)))- |
| hydrogen (6r-(6alpha,7beta(r*)))-4-carbamoyl-1-((2-carboxylato-8-oxo-7-(phenylsulphonatoacetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)pyridinium, monosodium salt |
| sce 129 |
| abbott-468 11 |
| cefsulodin sodium [usan:jan] |
| pyridinium, 4-(aminocarbonyl)-1-((2-carboxy-8-oxo-7-((phenylsulfoacetyl)amino)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, hydroxide, inner salt, monosodium salt, (6r-(6alpha,7beta(r*))) |
| einecs 257-692-4 |
| ulfaret |
| cgp 7174e |
| pyocefal |
| cefomonil |
| 4-carbamoyl-1-(((6r,7r)-2-carboxy-8-oxo-7-((2r)-2-phenyl-2-sulfoacetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)pyridinium hydroxide, inner salt, monosodium salt |
| pyridinium, 4-(aminocarbonyl)-1-(((6r,7r)-2-carboxy-8-oxo-7-(((2r)-phenylsulfoacetyl)amino)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, monosodium salt |
| 4-carbamoyl-1-(((6r,7r)-2-carboxy-8-oxo-7-((2r)-2-phenyl-2-sulfoacetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methylpyridinium hydroxide, inner salt, monosodium salt |
| PRESTWICK_977 |
| cefsulodin sodium |
| takesulin (tn) |
| D02005 |
| cefsulodin sodium (jp17/usan) |
| abbott 46811 |
| NCGC00093718-01 |
| C-2492 |
| C-2490 |
| cefsulodin sodium salt (sce-129), antibiotic for culture media use only |
| C 8145 |
| HMS1570D09 |
| NCGC00093718-02 |
| HMS3260D20 |
| HMS2097D09 |
| C2598 |
| nsc-758163 |
| pyridinium, 4-(aminocarbonyl)-1-(((6r,7r)-2-carboxy-8-oxo-7-(((2r)-2-phenyl-2-sulfoacetyl)amino)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, sodium salt (1:1) |
| unii-2d087186py |
| 2d087186py , |
| nsc 758163 |
| LP00259 |
| AKOS015896482 |
| CCG-221563 |
| CCG-220814 |
| cefsulodin sodium [mart.] |
| pyridinium, 4-(aminocarbonyl)-1-((2-carboxy-8-oxo-7-((phenylsulfoacetyl)amino)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, hydroxide, inner salt, monosodium salt, (6r-(6.alpha.,7.beta.(r*))) |
| cefsulodin sodium salt [mi] |
| cefsulodin sodium [jan] |
| cgp-71741e |
| 4-carbamoyl-1-[[(6r,7r)-2-carboxy-8-oxo-7-[(2r)-2-phenyl-2-sulfoacetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methylpyridinium hydroxide, inner salt, monosodium salt |
| cefsulodin sodium [usan] |
| cefsulodin sodium [who-dd] |
| SCHEMBL1648651 |
| NCGC00260944-01 |
| cefsulodin (sodium) , |
| tox21_500259 |
| CHEMBL1590946 |
| CHEBI:31380 , |
| (6r,7r)-3-[(4-carbamoylpyridin-1-ium-1-yl)methyl]-8-oxo-7-[[(2r)-2-phenyl-2-sulfonato-acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate |
| mfcd07793338 |
| AS-60551 |
| cefsulodin sodium salt, hydrate |
| HMS3714D09 |
| sodium (6r,7r)-3-((4-carbamoylpyridin-1-ium-1-yl)methyl)-8-oxo-7-((r)-2-phenyl-2-sulfonatoacetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate , |
| cefsulodin sodium salt 97%, for biochemistry |
| sodium;(6r,7r)-3-[(4-carbamoylpyridin-1-ium-1-yl)methyl]-8-oxo-7-[[(2r)-2-phenyl-2-sulfonatoacetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate |
| sodium(6r,7r)-3-((4-carbamoylpyridin-1-ium-1-yl)methyl)-8-oxo-7-((r)-2-phenyl-2-sulfonatoacetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| organic molecular entity | Any molecular entity that contains carbon. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (14)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 21.1546 | 0.0032 | 45.4673 | 12,589.2998 | AID1705; AID2517 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 7.8435 | 0.0040 | 23.8416 | 100.0000 | AID485290; AID489007 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 25.1189 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| endonuclease IV | Escherichia coli | Potency | 1.7783 | 0.7079 | 12.4324 | 31.6228 | AID1708 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 30.2586 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 0.1585 | 0.1800 | 13.5574 | 39.8107 | AID1468 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 8.9125 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 10.0000 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 39.8107 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 28.1838 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 3.1623 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 11.5189 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 25.1189 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 56.2341 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (77)
Molecular Functions (26)
Ceullar Components (22)
Bioassays (14)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1280565 | Inhibition of Mycobacterium tuberculosis PTPB | 2015 | ACS medicinal chemistry letters, Dec-10, Volume: 6, Issue:12 | Cefsulodin Inspired Potent and Selective Inhibitors of mPTPB, a Virulent Phosphatase from Mycobacterium tuberculosis. |
| AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID1470752 | Trypanocidal activity against trypomastigote stage of Trypanosoma cruzi INC-5 infected in NIH mouse blood after 24 hrs by optical microscopic method | 2017 | European journal of medicinal chemistry, May-26, Volume: 132 | An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method. |
| AID1470754 | Trypanocidal activity against trypomastigote stage of Trypanosoma cruzi NINOA infected in NIH mouse blood after 24 hrs by optical microscopic method | 2017 | European journal of medicinal chemistry, May-26, Volume: 132 | An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method. |
| AID1470755 | Inhibition of Trypanosoma cruzi trans-sialidase at 1 mM using N-acetyllactosamine as substrate in presence of 3'-sialyllactose measured after 15 mins by HPAEC-PAD relative to control | 2017 | European journal of medicinal chemistry, May-26, Volume: 132 | An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method. |
| AID1470761 | Trypanocidal activity against bloodstream form of Trypanosoma cruzi NINOA infected in NIH mouse assessed as reduction in parasitemia at 100 mg/kg, po measured at 6 hrs post dose by microscopic method | 2017 | European journal of medicinal chemistry, May-26, Volume: 132 | An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method. |
| AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID1470753 | Trypanocidal activity against trypomastigote stage of Trypanosoma cruzi NINOA infected in NIH mouse blood assessed as parasite lysis at 50 ug/ml after 24 hrs by optical microscopic method relative to control | 2017 | European journal of medicinal chemistry, May-26, Volume: 132 | An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method. |
| AID1470751 | Trypanocidal activity against trypomastigote stage of Trypanosoma cruzi INC-5 infected in NIH mouse blood assessed as parasite lysis at 50 ug/ml after 24 hrs by optical microscopic method relative to control | 2017 | European journal of medicinal chemistry, May-26, Volume: 132 | An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method. |
| AID1470760 | Trypanocidal activity against bloodstream form of Trypanosoma cruzi NINOA infected in NIH mouse assessed as reduction in parasitemia at 100 mg/kg, po measured at 2 to 4 hrs post dose by microscopic method | 2017 | European journal of medicinal chemistry, May-26, Volume: 132 | An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 40.16
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (40.16) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||